GENI Share Price Performance
UK£0.011
-0.02 (-69.72%)
85.7% undervalued intrinsic discount
UK£0.075
Fair Value
Price UK£0.011
AnalystConsensusTarget UK£0.075
Fair ValueUK£0.075
Share Pricen/a
GENinCode Plc Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
GENI Community Narratives
AN
Fair Value UK£0.075 85.7% undervalued intrinsic discount
Future Clinical Acceptance Of Genetic Risk Scoring Will Support Long Term Earnings Potential
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Future Clinical Acceptance Of Genetic Risk Scoring Will Support Long Term Earnings Potential
Catalysts About GENinCode GENinCode develops and commercialises genetic tests that aim to improve risk assessment and prevention in cardiovascular disease and certain cancers. What are the underlying business or industry changes driving this perspective?Read more
13
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
UK£0.075
85.7% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
35.21% p.a.
Profit Margin
4.75%
Future PE
77.25x
Price in 2029
UK£0.09
Trending Discussion
Recently Updated Narratives
AN
Future Clinical Acceptance Of Genetic Risk Scoring Will Support Long Term Earnings Potential
Fair Value: UK£0.075 85.7% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
GENinCode Plc Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.0066
- 53.02%
- -170.49%
- 0%
About GENI
- Founded
- 2018
- Employees
- 42
- CEO
- WebsiteView website
GENinCode Plc develops and commercializes clinical genetic tests to provide predictive analysis of risk to a patient’s health based on their genes in the United Kingdom and internationally. Its predictive technology offers patients and physicians with preventative care and treatment strategies. The company’s invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a genetic test to help user to adopt cardiovascular prevention assesment; Lipid inCode, a genetic diagnostic test for familial hypercholesterolemia FH; SUDD inCode, genetic diagnostic test for familial heart diseases; Thrombo inCode, a genetic test for diagnosis of hereditary thrombophilia and the risk of thrombosis. In addition, the company offers Thrombo inCode Reproductive Health, is a genetic test that evaluates the impact of hereditary thrombophilia in patients with repeated miscarriages; and ROCA Test, a blood test that determines the risk of a woman having ovarian cancer. Further, it engages in the medical and scientific research activities. GENinCode Plc was incorporated in 2018 and is based in Manchester, the United Kingdom.
